URL has been copied successfully!
GoodRx Holdings, Inc. (NASDAQ:GDRX) shares are gaining during Thursday’s premarket session.
The company revealed that it is expanding access to Eli Lilly and Company’s (NYSE:LLY) new oral GLP-1 medication, Foundayo.
GoodRx announced that eligible self-pay consumers can access Foundayo starting at $149 per month.
The company is also expanding access to Zepbound, available to eligible self-pay patients starting at $299 per …
Please follow us:
This post was originally published here
